Data on Colitis Discussed by a Researcher at University of Texas Health Science Center (Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor-Related Colitis in Patients with Cancer).
In: Gastroenterology Week, 2024-06-07, S. 204-204
serialPeriodical
Zugriff:
A researcher at the University of Texas Health Science Center has conducted a retrospective analysis of cancer patients with immune checkpoint inhibitor-related colitis (IMC) who were treated with budesonide. The study found that budesonide may be an effective strategy for treating and preventing the recurrence of IMC. The remission rates observed with budesonide were comparable to systemic corticosteroids, but with a lower risk of infection and complications. However, larger prospective studies are needed to determine the role of budesonide and its safety profile. [Extracted from the article]
Copyright of Gastroenterology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Data on Colitis Discussed by a Researcher at University of Texas Health Science Center (Outcomes of Budesonide as a Treatment Option for Immune Checkpoint Inhibitor-Related Colitis in Patients with Cancer).
|
---|---|
Zeitschrift: | Gastroenterology Week, 2024-06-07, S. 204-204 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6756 (print) |
Schlagwort: |
|
Sonstiges: |
|